I agree. I guess some are indiscriminantly lumping IMU in with...

I agree. I guess some are indiscriminantly lumping IMU in with those other 1/4 of biotechs which may face financial difficulty in the coming months. Certainly this is not the case here. IMU is one of few which will run cash flow positive... a very strong position in these turbulent times. IMO DYOR



Extract from the Quarterly Report

October – December 2008 - Quarter Highlights:
-Strategic Alliance signed with Merial Limited – 31 December 2008
-Initial income totaling US$2 million (AUD$2.9 million) received on 31 December 2008
-Strategic Alliance income exceeds AUD$30 million to Imugene within next 7 years
-Additional income from further sub-license fees and milestone payments on individual products and ultimately royalties on sales
-Imugene translates recent trial successes into a solid income stream
-Cashflow positive for the half year
-Strong cash income stream from IP achieved well in advance of product sales
-Imugene now in a secure financial position moving forward
-No foreseeable need to raise further capital